Both Perrigo and Teva are down on the Tel Aviv Stock Exchange following the Independence Day break.
After US-Israeli pharmaceuticals company Perrigo (PRGO) rejected Mylan’s (MYL) takeover bid last Tuesday, on Friday, Mylan announced an improved offer worth $31.8 billion. The original offer was $29 billion, or $205 per share.
Mylan is new offering $60 cash and 2.2 of its shares for each Perrigo share, valuing Perrigo shares at about $222 each.
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Published by Globes [online], Israel business news – www.globes-online.com
–
